Literature DB >> 2837227

Reduced DNA topoisomerase II activity and drug-stimulated DNA cleavage in 9-hydroxyellipticine resistant cells.

J Y Charcosset1, J M Saucier, A Jacquemin-Sablon.   

Abstract

We have isolated a Chinese hamster lung cell line resistant to 9-hydroxyellipticine (DC-3F/9-OH-E) which is also cross-resistant to topoisomerase II inhibitors such as amsacrine and etoposide. In this work we have studied quantitatively both DNA topoisomerase II activity by decatenation of kinetoplast DNA and drug-stimulated DNA cleavage of pBR 322. DNA topoisomerase II activity of DC-3F/9-OH-E nuclear extract was reduced by 3.5-fold as compared to that from DC-3F (sensitive parent) nuclear extract. We also found that DC-3F/9-OH-E nuclear extracts have a reduced capacity to induce in vitro topoisomerase II-mediated DNA cleavage upon stimulation by etoposide and amsacrine (7- and 10-fold respectively). Besides, mixing nuclear extracts from both sensitive and resistant cells indicates that either the enzyme in resistant cells is modified or a modulating factor is associated to it. Our results suggest that the resistance of the DC-3F/9-OH-E cell line to topoisomerase II inhibitors might be due to both a reduced amount of the enzyme and its reduced ability to form the cleavable complex in the presence of drugs.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2837227     DOI: 10.1016/0006-2952(88)90573-4

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

1.  In vitro cytotoxicity of S16020-2, a new olivacine derivative.

Authors:  S Léonce; V Perez; M R Casabianca-Pignede; M Anstett; E Bisagni; A Pierré; G Atassi
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

2.  Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide.

Authors:  B Y Bugg; M K Danks; W T Beck; D P Suttle
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

Review 3.  Anthracycline antibiotics in cancer therapy. Focus on drug resistance.

Authors:  D J Booser; G N Hortobagyi
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

4.  Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells.

Authors:  K Bojanowski; S Lelievre; J Markovits; J Couprie; A Jacquemin-Sablon; A K Larsen
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

5.  Novel selection and genetic characterisation of an etoposide-resistant human leukaemic CCRF-CEM cell line.

Authors:  S Patel; L M Fisher
Journal:  Br J Cancer       Date:  1993-03       Impact factor: 7.640

6.  Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells.

Authors:  M K Ritke; D Roberts; W P Allan; J Raymond; V V Bergoltz; J C Yalowich
Journal:  Br J Cancer       Date:  1994-04       Impact factor: 7.640

7.  Mechanisms of resistance to combinations of vincristine, etoposide and doxorubicin in Chinese hamster ovary cells.

Authors:  S Souès; F Laval; J Y Charcosset
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.